Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can-Fite Biopharma Ltd Sponsored ADR (Israel) is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Can-Fite Biopharma Ltd Sponsored ADR (Israel) is not a good growth stock. Can-Fite Biopharma Ltd Sponsored ADR (Israel) is not very popular among insiders. Can-Fite Biopharma Ltd Sponsored ADR (Israel) is a mediocre stock to choose.
Log in to see more information.
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on dev...
CANF Fundamental Data by TradingView

News

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Globe Newswire RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs...\n more…

Can-Fite Provides Namodenoson Patent Update
Can-Fite Provides Namodenoson Patent Update

Globe Newswire Broad Protection of Namodenoson is expected till at least 2044 PETACH TIKVA, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology...\n more…

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Globe Newswire RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs...\n more…

Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Globe Newswire Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI...\n more…